Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pneumonia survivors face hidden heart risks – new study aims to find out why

NCT ID NCT06601998

Knowledge-focused Sponsor: Hellenic Institute for the Study of Sepsis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study follows 650 adults who had pneumonia (including COVID-19) to see how the infection might lead to heart disease later. Researchers will collect blood samples, run heart and lung tests, and track heart attacks, strokes, and other events over three years. No new treatment is being tested; the goal is to better understand the link between lung infections and cardiovascular problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors identify which pneumonia survivors are at higher risk for heart attacks or strokes, and point toward ways to prevent those events.
What could go wrong
This is an observational study, not a treatment trial. It will not test any new drug or therapy, so it cannot directly improve health. Results may take years to influence medical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 650 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study needs to enroll four groups of patients to cover the magnitude of the spectrum of community-acquired pneumonia and enroll the required controls: * Group A: Controls with no or one comorbidity, predisposing to significant CV events and without a medical history of severe pneumonia. This group is important to provide baseline biological values and control samples to investigate normal host-microbiome interactions. No follow-up is performed for healthy controls. * Group B: Controls with comorbidities predisposing to major CV events and without a medical history of severe pneumonia. This group is important to provide normal CVRD progression in patients at risk and control samples for the investigation of host-microbiome interactions in patients with stable CVRD. * Group C: Patients cured of acute COVID-19. * Group D: Patients cured of severe community-acquired pneumonia.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Group A (healthy controls) 1. Adults (18 years or more) of both genders (Female/Male: 50/50 ratio) 2. No history of severe pneumonia (sCAP, COVID-19 or HAP) 3. Presence of no or one of the following comorbidities: obesity (defined as body mass index over 35 kg/m2), type 2 diabetes mellitus, hypercholesterolemia, essential arterial hypertension, or familial history of CVD. Group B (CVRD controls) 1. Adults (18 years or more) of both genders (Female/Male ratio: 50/50) 2. No history of severe pneumonia (sCAP, COVID-19 or HAP) 3. At least two of the following comorbidities: obesity (defined as body mass index over 35 kg/m2), type 2 diabetes mellitus, hypercholesterolemia, essential arterial hypertension, or familial history of CVD Group C (COVID-19 survivors) 1. Adults (18 years or more) of both genders (Female/Male ratio: 50/50) 2. Survivors from severe COVID-19 pneumonia at hospital discharge; all patients had consolidation in chest X-ray or chest computed tomography during acute infection and were treated for pneumonia 3. SoC treatment for acute COVID-19 with dexamethasone Group D (sCAP survivors) 1. Adults (18 years or more) of both genders 2. Survivors from sCAP pneumonia; these patients may be either hospitalized in the ward with pO2FiO2 ratio less than 300 or require admission and hospitalization in the Intensive Care Unit. 3. SoC treatment for sCAP with antibiotics Exclusion Criteria: Group A (healthy controls) 1. Presence of two or more comorbidities 2. Any other co-existing disorder generating CVRD symptoms 3. Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians 4. Pregnancy or lactation Group B (CVRD controls) 1. Any other co-existing disorder generating CVRD symptoms 2. Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians 3. Pregnancy or lactation Group C (COVID-19 survivors) 1. Medical history of severe congestive heart failure (Stage III-IV) 2. Medical history of stage III or IV dyspnoea according to the New York Heart Association classification before the acute COVID-19 3. Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians 4. Pregnancy or lactation Group D (sCAP survivors) 1. Medical history of severe congestive heart failure (Stage III-IV) 2. Medical history of stage III or IV dyspnoea according to the New York Heart Association classification before the sCAP 3. Limited chance of survival for at least six months due to co-existing comorbidity (-ies) according to the judgement of the attending physicians 4. Pregnancy or lactation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder Community-Acquired Pneumonia COVID-19 pneumonia Respiration Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular diseases COVID-19 pneumonia Pneumonia, community-acquired

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    18 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • 10th Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases

    RECRUITING

    Athens, Greece

  • 1st Department of Internal Medicine, AHEPA University General Hospital of Thessaloniki

    NOT_YET_RECRUITING

    Thessaloniki, Greece

  • 1st Department of Internal Medicine, General Hospital of Athens G. GENNIMATAS

    RECRUITING

    Athens, Greece

  • 1st Department of Internal Medicine, General Hospital of Athens KORGIALENIO-BENAKIO E.E.S.

    RECRUITING

    Athens, Greece

  • 1st Department of Internal Medicine, General Hospital of Voula ASKLEPIEIO

    RECRUITING

    Athens, Greece

  • 1st Department of Internal Medicine, Thriasio General Hospital of Elefsina

    NOT_YET_RECRUITING

    Elefsina, Greece

  • 1st Intensive Care Clinic of the Medical School of the University of Athens, Evangelismos General Hospital

    RECRUITING

    Athens, Greece

  • 1st University Department of Internal Medicine, General Hospital of Athens LAIKO

    RECRUITING

    Athens, Greece

  • 1st University Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases

    RECRUITING

    Athens, Greece

  • 2nd Department of Internal Medicine, General Hospital of Voula ASKLEPIEIO

    RECRUITING

    Athens, Greece

  • 2nd Department of Internal Medicine, University General Hospital of Alexandroupolis

    NOT_YET_RECRUITING

    Alexandroupoli, Greece

  • 2nd Department of Pulmonary Medicine, Sotiria Athens Hospital of Chest Diseases

    RECRUITING

    Athens, Greece

  • 3rd University Department of Internal Medicine, Sotiria Athens Hospital of Chest Diseases

    RECRUITING

    Athens, Greece

  • 4th Department of Internal Medicine, ATTIKON University General Hospital

    RECRUITING

    Athens, Greece

  • Intensive Care Unit 2, AHEPA University General Hospital of Thessaloniki

    NOT_YET_RECRUITING

    Thessaloniki, Greece

  • Intensive Care Unit, "Ippokrateion" General Hospital of Thessaloniki

    NOT_YET_RECRUITING

    Thessaloniki, Greece

  • Intensive Care Unit, General Hospital of Voula ASKLEPIEIO

    RECRUITING

    Athens, Greece

  • Out-patients clinic, General Hospital of Voula ASKLEPIEIO

    RECRUITING

    Athens, Greece

More trials for these conditions

Other studies related to the condition(s) this trial covers.